Phase II trial of rituximab plus CVP combination chemotherapy for advanced stage marginal zone lymphoma as a first-line therapy: Consortium for Improving Survival of Lymphoma (CISL) study

Hye Jin Kang, Won Seog Kim, Seok Jin Kim, Je Jung Lee, Deok Hwan Yang, Jin Seok Kim, Se Ryeon Lee, Gyeong Won Lee, Hyo Jung Kim, Ho Young Kim, Sung Yong Oh, Hugh Chul Kim, Hyeon Seok Eom, Jooseop Chung, Jinny Park, Cheolwon Suh, Baek Yeol Ryoo

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

We conducted a multicenter, phase II trial to investigate the efficacy and safety of rituximab plus CVP (R-CVP) combination therapy for patients with previously untreated stage III or IV marginal zone lymphoma (MZL). The treatment consisted of rituximab 375 mg/m 2, cyclophosphamide 750 mg/m 2 and vincristine 1.4 mg/m 2 (maximum 2.0 mg) being given intravenously on day 1 and oral prednisolone 100 mg on days 1-5. The treatment was repeated every 3 weeks and this was continued for six or eight cycles. Forty-two patients were enrolled from 13 institutes in Korea. Among them, two patients were dropped after the first and second cycles of chemotherapy, respectively, without evaluation. The 40 patients received a total of 287 cycles of R-CVP chemotherapy. The overall response rate was 88% (95% CI, 77-98%) with 24 complete responses (60%). The median duration of response was 28.3 months. After a median follow-up of 38.2 months, the estimated 3-year progression-free survival and overall survival were 59% and 95%, respectively. There were 30/287 cycles (11%) and 5/287 cycles (2%) of grade 3 or 4 neutropenia and febrile neutropenia, respectively. The R-CVP regimen can be an effective and tolerable first-line immunochemotherapy regimen for advanced stage MZL.

Original languageEnglish
Pages (from-to)543-551
Number of pages9
JournalAnnals of Hematology
Volume91
Issue number4
DOIs
Publication statusPublished - 2012 Apr 1

Fingerprint

Combination Drug Therapy
Lymphoma
Survival
Drug Therapy
Febrile Neutropenia
Vincristine
Therapeutics
Korea
Prednisolone
Neutropenia
Cyclophosphamide
Disease-Free Survival
Safety
Rituximab

Keywords

  • CVP
  • First-line
  • Immunochemotherapy
  • Marginal zone lymphoma
  • Rituximab

ASJC Scopus subject areas

  • Hematology

Cite this

Phase II trial of rituximab plus CVP combination chemotherapy for advanced stage marginal zone lymphoma as a first-line therapy : Consortium for Improving Survival of Lymphoma (CISL) study. / Kang, Hye Jin; Kim, Won Seog; Kim, Seok Jin; Lee, Je Jung; Yang, Deok Hwan; Kim, Jin Seok; Lee, Se Ryeon; Lee, Gyeong Won; Kim, Hyo Jung; Kim, Ho Young; Oh, Sung Yong; Kim, Hugh Chul; Eom, Hyeon Seok; Chung, Jooseop; Park, Jinny; Suh, Cheolwon; Ryoo, Baek Yeol.

In: Annals of Hematology, Vol. 91, No. 4, 01.04.2012, p. 543-551.

Research output: Contribution to journalArticle

Kang, HJ, Kim, WS, Kim, SJ, Lee, JJ, Yang, DH, Kim, JS, Lee, SR, Lee, GW, Kim, HJ, Kim, HY, Oh, SY, Kim, HC, Eom, HS, Chung, J, Park, J, Suh, C & Ryoo, BY 2012, 'Phase II trial of rituximab plus CVP combination chemotherapy for advanced stage marginal zone lymphoma as a first-line therapy: Consortium for Improving Survival of Lymphoma (CISL) study', Annals of Hematology, vol. 91, no. 4, pp. 543-551. https://doi.org/10.1007/s00277-011-1337-6
Kang, Hye Jin ; Kim, Won Seog ; Kim, Seok Jin ; Lee, Je Jung ; Yang, Deok Hwan ; Kim, Jin Seok ; Lee, Se Ryeon ; Lee, Gyeong Won ; Kim, Hyo Jung ; Kim, Ho Young ; Oh, Sung Yong ; Kim, Hugh Chul ; Eom, Hyeon Seok ; Chung, Jooseop ; Park, Jinny ; Suh, Cheolwon ; Ryoo, Baek Yeol. / Phase II trial of rituximab plus CVP combination chemotherapy for advanced stage marginal zone lymphoma as a first-line therapy : Consortium for Improving Survival of Lymphoma (CISL) study. In: Annals of Hematology. 2012 ; Vol. 91, No. 4. pp. 543-551.
@article{578e2512bd0f45c091f8e18f7242339e,
title = "Phase II trial of rituximab plus CVP combination chemotherapy for advanced stage marginal zone lymphoma as a first-line therapy: Consortium for Improving Survival of Lymphoma (CISL) study",
abstract = "We conducted a multicenter, phase II trial to investigate the efficacy and safety of rituximab plus CVP (R-CVP) combination therapy for patients with previously untreated stage III or IV marginal zone lymphoma (MZL). The treatment consisted of rituximab 375 mg/m 2, cyclophosphamide 750 mg/m 2 and vincristine 1.4 mg/m 2 (maximum 2.0 mg) being given intravenously on day 1 and oral prednisolone 100 mg on days 1-5. The treatment was repeated every 3 weeks and this was continued for six or eight cycles. Forty-two patients were enrolled from 13 institutes in Korea. Among them, two patients were dropped after the first and second cycles of chemotherapy, respectively, without evaluation. The 40 patients received a total of 287 cycles of R-CVP chemotherapy. The overall response rate was 88{\%} (95{\%} CI, 77-98{\%}) with 24 complete responses (60{\%}). The median duration of response was 28.3 months. After a median follow-up of 38.2 months, the estimated 3-year progression-free survival and overall survival were 59{\%} and 95{\%}, respectively. There were 30/287 cycles (11{\%}) and 5/287 cycles (2{\%}) of grade 3 or 4 neutropenia and febrile neutropenia, respectively. The R-CVP regimen can be an effective and tolerable first-line immunochemotherapy regimen for advanced stage MZL.",
keywords = "CVP, First-line, Immunochemotherapy, Marginal zone lymphoma, Rituximab",
author = "Kang, {Hye Jin} and Kim, {Won Seog} and Kim, {Seok Jin} and Lee, {Je Jung} and Yang, {Deok Hwan} and Kim, {Jin Seok} and Lee, {Se Ryeon} and Lee, {Gyeong Won} and Kim, {Hyo Jung} and Kim, {Ho Young} and Oh, {Sung Yong} and Kim, {Hugh Chul} and Eom, {Hyeon Seok} and Jooseop Chung and Jinny Park and Cheolwon Suh and Ryoo, {Baek Yeol}",
year = "2012",
month = "4",
day = "1",
doi = "10.1007/s00277-011-1337-6",
language = "English",
volume = "91",
pages = "543--551",
journal = "Annals of Hematology",
issn = "0939-5555",
publisher = "Springer Verlag",
number = "4",

}

TY - JOUR

T1 - Phase II trial of rituximab plus CVP combination chemotherapy for advanced stage marginal zone lymphoma as a first-line therapy

T2 - Consortium for Improving Survival of Lymphoma (CISL) study

AU - Kang, Hye Jin

AU - Kim, Won Seog

AU - Kim, Seok Jin

AU - Lee, Je Jung

AU - Yang, Deok Hwan

AU - Kim, Jin Seok

AU - Lee, Se Ryeon

AU - Lee, Gyeong Won

AU - Kim, Hyo Jung

AU - Kim, Ho Young

AU - Oh, Sung Yong

AU - Kim, Hugh Chul

AU - Eom, Hyeon Seok

AU - Chung, Jooseop

AU - Park, Jinny

AU - Suh, Cheolwon

AU - Ryoo, Baek Yeol

PY - 2012/4/1

Y1 - 2012/4/1

N2 - We conducted a multicenter, phase II trial to investigate the efficacy and safety of rituximab plus CVP (R-CVP) combination therapy for patients with previously untreated stage III or IV marginal zone lymphoma (MZL). The treatment consisted of rituximab 375 mg/m 2, cyclophosphamide 750 mg/m 2 and vincristine 1.4 mg/m 2 (maximum 2.0 mg) being given intravenously on day 1 and oral prednisolone 100 mg on days 1-5. The treatment was repeated every 3 weeks and this was continued for six or eight cycles. Forty-two patients were enrolled from 13 institutes in Korea. Among them, two patients were dropped after the first and second cycles of chemotherapy, respectively, without evaluation. The 40 patients received a total of 287 cycles of R-CVP chemotherapy. The overall response rate was 88% (95% CI, 77-98%) with 24 complete responses (60%). The median duration of response was 28.3 months. After a median follow-up of 38.2 months, the estimated 3-year progression-free survival and overall survival were 59% and 95%, respectively. There were 30/287 cycles (11%) and 5/287 cycles (2%) of grade 3 or 4 neutropenia and febrile neutropenia, respectively. The R-CVP regimen can be an effective and tolerable first-line immunochemotherapy regimen for advanced stage MZL.

AB - We conducted a multicenter, phase II trial to investigate the efficacy and safety of rituximab plus CVP (R-CVP) combination therapy for patients with previously untreated stage III or IV marginal zone lymphoma (MZL). The treatment consisted of rituximab 375 mg/m 2, cyclophosphamide 750 mg/m 2 and vincristine 1.4 mg/m 2 (maximum 2.0 mg) being given intravenously on day 1 and oral prednisolone 100 mg on days 1-5. The treatment was repeated every 3 weeks and this was continued for six or eight cycles. Forty-two patients were enrolled from 13 institutes in Korea. Among them, two patients were dropped after the first and second cycles of chemotherapy, respectively, without evaluation. The 40 patients received a total of 287 cycles of R-CVP chemotherapy. The overall response rate was 88% (95% CI, 77-98%) with 24 complete responses (60%). The median duration of response was 28.3 months. After a median follow-up of 38.2 months, the estimated 3-year progression-free survival and overall survival were 59% and 95%, respectively. There were 30/287 cycles (11%) and 5/287 cycles (2%) of grade 3 or 4 neutropenia and febrile neutropenia, respectively. The R-CVP regimen can be an effective and tolerable first-line immunochemotherapy regimen for advanced stage MZL.

KW - CVP

KW - First-line

KW - Immunochemotherapy

KW - Marginal zone lymphoma

KW - Rituximab

UR - http://www.scopus.com/inward/record.url?scp=84860805905&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860805905&partnerID=8YFLogxK

U2 - 10.1007/s00277-011-1337-6

DO - 10.1007/s00277-011-1337-6

M3 - Article

C2 - 21922208

AN - SCOPUS:84860805905

VL - 91

SP - 543

EP - 551

JO - Annals of Hematology

JF - Annals of Hematology

SN - 0939-5555

IS - 4

ER -